SCHEMBL557497

SCHEMBL557497

COC(=O)c1ccn2c(I)cnc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.42
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 7/20 0.40
KDM6B O15054 1/20 0.40
KDM5C P41229 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM2A Q9Y2K7 1/20 0.40
KDM3A Q9Y4C1 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
XDH P47989 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 5/20 0.39
GAA P10253 3/20 0.39
GLA P06280 2/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3185876 0.85 FLT3 (0.43) MAPK1KDM4ECA12CA1CA2
SCHEMBL24492953 0.84 JMJD6 (0.43) JMJD6MAPK1KDM4EKDM6BKDM5C
SCHEMBL10138740 0.83 KDM4E (0.39) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2660202 0.82 JMJD6 (0.42) JMJD6MAPK1KDM4EKDM6BKDM5C
SCHEMBL17350560 0.82 RIPK2 (0.44) KDM4EALDH1A1GAAAKT1AKT2
SCHEMBL563331 0.81 KDM4E (0.43) JMJD6KDM4EKDM6BKDM5CKDM4C
SCHEMBL23426038 0.81 PLAU (0.41) KDM4EALDH1A1HPGDPKM
SCHEMBL557149 0.80 RIPK2 (0.39) KDM4EALDH1A1GAAHPGDAKT1
SCHEMBL24997460 0.80 ALDH1A1 (0.41) JMJD6MAPK1KDM4EKDM6BKDM5C
SCHEMBL2396747 0.80 JMJD6 (0.40) JMJD6MAPK1KDM4EKDM6BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728965-B Pyrido heterocyclic compounds, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-28 CN disclosed
CN-114728965-A Pyridino-heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2022-07-08 CN disclosed
WO-2022082009-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF EPIRIUM BIO INC. (US) 2022-04-21 WO disclosed
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 US disclosed
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-10-29 US disclosed
CN-111225917-A Substituted imidazopyridine amides and uses thereof 拜耳股份公司 2020-06-02 CN disclosed
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
EP-2419427-B1 BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE ASTEX THERAPEUTICS LTD (GB) 2016-04-06 EP disclosed
EP-2197880-B1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-12-23 EP disclosed
EP-2114941-B1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-03-25 EP disclosed
WO-2009047522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2009047506-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2009047506-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 WO disclosed
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 US disclosed
WO-2008027812-A2 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 WO disclosed
WO-2008027812-A2 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 WO disclosed
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 US disclosed
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058350-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES CNR2, CNR1, P2RY4 JMJD6 2614/4885MAPK1 2043/4885KDM4E 1477/4885
US-20200339567-A1 SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF GOT2, ABAT, OAT JMJD6 2888/4885MAPK1 837/4885KDM4E 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.